MediCom Oncology Clinical Pearl Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting, in under three minutes. Leading experts and academic faculty from top research and practice institutions provide guidance to community-based healthcare providers,…
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.
Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.
In this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS).
Listen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant.
Hematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.
Dr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.
Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.
Listen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.
Listen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy.
Listen as Dr. Matasar discusses survivorship care for patients who have been treated for classical Hodgkin lymphoma, including late effects of treatment.
Dr. Jacob Laubach discusses second primary malignancies associated with lenalidomide maintenance in the transplant and post-transplant setting.
Dr. Laubach discusses the impact of consolidation therapy in patients post-transplant, referencing results of the CTN StaMINA trial.
Dr. Jacob Laubach discusses bortezomib as an alternate strategy to lenalidomide for maintenance therapy in patients with multiple myeloma.
Listen as Dr. Matasar discusses the future role of brentuximab vedotin in patients with newly diagnosed classical Hodgkin lymphoma.
Dr. Ruben Niesvizky discusses MRD testing and how it has become a standard of care in multiple myeloma, as well as future directions in MRD testing that will improve outcomes in these patients.
Dr. O'Reilly provides an insightful overview of how the emerging use of precision medicine and the Precision Promise [SM] initiative will impact the new drug approval process in pancreatic cancer.
Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.
Dr. Ruben Niesvizky discusses newer approaches for imaging in patients who have multiple myeloma with bone disease, including the benefits of combining modalities such MRI and PET scan.
Dr. Ruben Niesvizky discusses clinical approaches to managing the risk of developing VTE in myeloma patients receiving immunomodulating agents such as lenalidomide or thalidomide.
In under two minutes, Dr. Carol Ann Huff will discuss how to dose daratumumab in conjunction with lenalidomide and dexamethasone in patients with multiple myeloma.
Dr. Anil Rustgi discusses a clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes.
Dr. Stuart Goldberg briefly summarizes updates on CPX-351, a liposomal form of cytarabine and daunorubicin that allows for office infusion vs. standard consolidation requiring hospitalization.
Listen as Dr. Huff discusses the infusion duration for carfilzomib in patients with multiple myeloma.
Listen as Dr. O'Reilly discusses the the current status of immunotherapy in pancreatic cancer.
Listen for just under two minutes as Dr. Harvey explains measuring frailty in patients being treated for multiple myeloma.
Dr. Eytan Stein provides a brief update on patients experiencing differentiation syndrome in a larger enasidenib trial, detailing the creation of a Differentiation Syndrome Review Committee.
Listen as Dr. Carol Ann Huff discusses how to dose daratumumab, bortezomib and dexamethasone in the combination regimen.
Listen as Dr. Philip McCarthy provides an update on the CALGB-100104 (Alliance) randomized trial.
Listen as Dr. Alison Moskowitz discusses the difference between the safety profile of the new and emerging anti-PD-1 antibodies and chemotherapy.
Listen as Dr. Alison Moskowitz discusses the safety profile of the new and emerging anti-PD1 antibodies and how this differs from traditional chemotherapy in just under two minutes.
Dr. Sagar Lonial provides a brief update on the ELOQUENT-2 phase 3 trial and how it continues to demonstrate a benefit in terms of progression-free survival.
Listen for just under two minutes as Dr. Harvey discusses optimal pre-medications for daratumumab, including H1 antagonists.
Listen as Dr. Harvey will discuss rash management for patients taking IRd.
Listen as Dr. Niesvizky explains the appropriate management for severe hypercalcemia.
Listen as Dr. Niesvizky discusses the most common cause of renal failure in newly diagnosed patients with MM.
Listen as Dr. Wang-Gillam discusses the standard dosing and delivery of Nal-IRI + 5-FU/LV.
Listen as Dr. Ritchie discusses the importance of available supportive care when considering transplant in older patients with MDS.
Listen as Dr. Moskowitz discusses the AE profile of BV and traditional monoclonal antibody therapies.
Listen as Dr. Richter discusses when you need to do a bone marrow biopsy in the management or assessment of multiple myeloma.
Listen as Dr. Moskowitz discusses the more common adverse reactions associated with brentuximab vedotin and how they are most often managed.
Listen as Dr. Richter will discuss the different technologies used to assess cytogenetic risk status in your myeloma patient.
Listen as Dr. Richter will discuss the meaning of high-risk myeloma.
Listen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of FOLFIRNOX in patients with pancreatic cancer.
Listen as Dr. Anas Younes covers the new FDA approval of pembrolizumab for patients with cHL.
Listen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of gemcitabine/nab-paclitaxel in patients with pancreatic cancer.
Listen as Dr. Rami Komrokji explains how to diagnose chronic myelomonocytic leukemia (CMML).
Listen as Dr. Rami Komrokji discusses what tests to obtain upfront at the time of MDS diagnosis.
Listen as Dr. Donald Harvey explains how to manage diarrhea in patients taking ixazomib.
Listen as Dr. Donald Harvey explains which prophylactic antithrombotic agents are safe to use with lenalidomide.
Listen as Dr. Donald Harvey explains how he manages renal dysfunction in a patient who is taking lenalidomide.
© 2020-2025 Ivy Podcast Discovery LLC
